pexelizumab

Phase 3Monoclonal antibody

AstraZeneca

pexelizumab is one of 70 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

Coronary Artery BypassActive, not recruiting

Acute Myocardial InfarctionPhase 3

Active, not recruiting

Coronary Artery BypassPhase 3

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Phase 3

1 2

Lovenox

Sanofi

Phase 3

1 3

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 4

Reopro

Boehringer Ingelheim

Phase 3

1 5

Glucophage

EMD Serono

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 7

Jardiance

Boehringer Ingelheim

Phase 3

1 8

Rayaldee

OOrganon and Co

Phase 3

1 9

Unfractionated Heparin

GSK

Phase 3

1 10

Ziltivekimab

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coronary Artery Bypass2 trials

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00048308·3,000 enrolled

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00088179·4,000 enrolled

Acute Myocardial Infarction1 trial

Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

Completed·PProcter and Gamble·Phase 3·NCT00091637·5,745 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for pexelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pexelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pexelizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

pexelizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coronary Artery Bypass2 trials

Acute Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News